DUX4 and facioscapulohumeral muscular dystrophy: The first use of the CRISPR system in FSHD was reported in 2016, when Himeda et al. utilized an inhibitor fused to a “dead” Cas9 (dCas9) to target the DUX4 promoter in FSHD myoblasts.